|

Saruparib Clinical Trials

4 actively recruiting trials across 4 locations

▼ -1 trial since May 2026

Also known as: 2589531-76-8, AZD 5305, AZD-5305, AZD5305, PARP Inhibitor AZD5305

Pipeline

Early 1: 1Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

  • AstraZeneca2
  • SWOG Cancer Research Network1
  • OHSU Knight Cancer Institute1

Indications

  • Cancer4
  • Locally Advanced Pancreatic Ductal Adenocarcinoma1
  • Lung Small Cell Carcinoma, P Subtype1
  • Lung Small Cell Carcinoma, N Subtype1
  • Lung Small Cell Carcinoma, I Subtype1

Phoenix, Arizona1 trial

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Research Site

Phase 3

Loma Linda, California1 trial

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Loma Linda University Medical Center

Phase 2

New York, New York1 trial

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Research Site

Phase 1/2

Portland, Oregon1 trial

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

OHSU Knight Cancer Institute

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.